Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
This study is currently recruiting participants.
Verified June 2013 by Boehringer Ingelheim Pharmaceuticals
Study NCT00987935   Information provided by Boehringer Ingelheim Pharmaceuticals

First Received on September 30, 2009.   Last Updated on June 12, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma, Hepatocellular
Additional conditions recognized in this trial
Carcinoma
More general conditions related to this trial
Adenocarcinoma
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Liver Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
Sorafenib
BIBF 1120
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services